

Transforming women's health through innovation

Company overview

Mithra is a Belgian **biotech company** created in 1999 dedicated to transforming **Women's Health** by offering new choices through innovation based on a unique molecule called Estetrol (E4), a native estrogen that offers a differentiated benefit/risk profile compared to existing hormone-based solutions.

Thanks to the commitment of its employees based on two sites, among which a majority of women, Mithra stands by its goals to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.

Mithra relies on **two complementary innovative platforms**: an Estetrol-based portfolio and Complex Therapeutics which are complemented by a unique manufacturing facility, Mithra CDMO and leveraged by Mithra's know-how in **long-acting drug development** using polymer technology.

Global strategy

Women's health

Estelle® is a contraceptive pill designed to improve women's contraceptive experience as it showed a favorable safety profile, a higher user satisfaction with improved quality of life and a low risk of drug-drug interaction.

Donesta® is a next generation orally-administrated estetrol-based hormone therapy product candidate.

and beyond

Neuroprotection and wound healing.

Complex therapeutics

Myring® Contraception

Tibelia® Menopause

Zoreline® Oncology

R&D pipeline

	Product	Indication	Preclinical	Phase I	Phase II	Phase III	Commercialization
E4	Estelle®	Contraception					
	Donesta®	Menopause					
	IVF	Fertility					
COMPLEX THERAPEUTICS	Myring®	Contraception					
	Tibelia®	Menopause					
	Zoreline®	Oncology					

Management



David Horn Solomon
Chief Executive Officer (CEO)



Christophe Maréchal
Chief Financial Officer (CFO)



Alex Sokolowski
Head of Investor Relations

ESG Rating




Financial overview

(in EUR million)

Revenues 7.0	R&D expenses (27.0)	REBITDA (33.7)	Net loss (50.5)
------------------------	-----------------------------------	--------------------------	---------------------------

Share information

Number of outstanding shares



Shareholders

%
(26 Sept. 2023)

Noshaq	7.94 %
Armistice Capital	14.47 %
François Fornieri	15.64 %
Other shareholders (<5%)	61.95 %

Cash position



Analyst Coverage



Last updated Sept 2023



Stay in touch!

Subscribe to our mailing list:
www.mithra.com/en/newsletter/



Further information

investorrelations@mithra.com
<https://www.mithra.com/en/investors/>